Telaprevir increases cure rate in hepatitis C study

05/26/2010 | New York Times (tiered subscription model), The

Hepatitis C drug telaprevir reduced the virus to an undetectable level in 75% of clinical-trial patients who received the standard dose in combination with interferon and ribavirin, Vertex Pharmaceuticals reported. The study focused on patients with Genotype 1 hepatitis C who had not received treatment before the trial.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA